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inﬂammation in one study,8 epidemiological studies have reported a
limited association between high choline and betaine intake and car
diovascular morbidity that was attenuated following adjustments for
other cardiovascular risk markers.9,10
There is a growing appreciation that intestinal microbiota can par
ticipate in metabolic phenotypes such as obesity and insulin resist
ance.11–13 Recently, through a series of animal and human studies,
our group has identiﬁed a direct mechanistic link between intestinal
microbiota dependent metabolism of trimethylamine (TMA)
containing dietary nutrients such as choline, PC, and carnitine and
production of trimethylamine N oxide (TMAO), a metabolite
shown to both alter cholesterol and sterol metabolism in multiple
compartments and to directly enhanced atherosclerosis in animal
models.14–16 Gut microbiota have been shown to play an obligate
role in TMAO formation from ingested choline, PC, and carnitine
in both animal models and humans.14,16 Moreover, elevated levels
of TMAOhavebeen shown to predict increased prevalent cardiovas
cular disease (CVD) risk, and increased incident risk ofmajor adverse
cardiovascular events (MACE ¼ myocardial infarction, stroke, and
death) in large scale human clinical studies.14,16,17 Betaine, an oxida
tion product of choline, is generally regarded as safe for dietary inges
tion. Surprisingly, although a TMA containing species, whether orally
ingested betaine produces TMAO or not is unknown. Moreover,
while elevated whole blood choline levels have been reported to
predict increased cardiovascular risk,18–21 the relationship between
TMAO and the clinical prognostic value of choline or betaine is
unknown. Herein, we show that oral ingestion of d9 betaine results
in generation of circulating levels of d9 TMAO in a gut microbiota
dependent fashion.We further examine the relationship between cir
culating levels of choline and betaine and development of cardiovascu
lar morbidity and mortality, and the impact of TMAO on this
relationship.
Methods
Study population
We prospectively recruited sequential stable subjects (n ¼ 3903) under
going elective, non urgent coronary angiography at the Cleveland Clinic
without any evidence of acute coronary syndrome (cardiac troponin I
≤0.03 ng/mL). All subjects were followed over a period of 3 years from
time of enrollment including adjudication of MACE(which includes the
future development of all cause mortality, non fatal myocardial
infarction, or non fatal stroke). Fasting blood glucose, high sensitivity
(hs) C reactive protein, and lipid proﬁles were measured on the Abbott
Architect ci8200 platform (Abbott Diagnostics, Abbott Park, IL, USA).
Mass spectrometry analyses
of trimethylamine-N-oxide,
choline, and betaine
Plasmawas immediately prepared from venous blood drawn into ethyle
nediaminetetraacetic acid tubes and then stored at 808C until analysis.
Trimethylamine N oxide, choline, and betaine levels in plasma were
determined using stable isotope dilution high performance liquid chro
matographywith on line electrospray ionization tandemmass spectrom
etry (LC/MS/MS) on either an AB SCIEX 5000 or AB SCIEX 5500 triple
quadrupole mass spectrometer using d9 (trimethyl) labelled internal
standards as described previously.14
Metabolic challenges in mice
Whole blood (50 mL) was collected via the saphenous vein fromC57BL/
6J mice prior to gavage for the measurement of baseline analyte levels.
Mice were administered an oral dose of stable isotope labelled betaine
or choline. The gavage consisted of 150 mL of either 150 mM betaine
N,N,N trimethyl d9 (d9 betaine, CDN Isotopes) or 150 mM choline
N,N,N trimethyl d9 (d9 choline, Cambridge Isotope Lab) followed by
post gavage blood collection at the indicated times. Where indicated,
gut microbiota were suppressed in mice as previously described14 by
placement of a cocktail of antibiotics in drinking water for 3 weeks
prior to the d9 betaine challenge. Ethylenediaminetetraacetic acid
plasma was generated following centrifugation at 1000 g for 20 min at
48C, and d9 labelled parent compounds andmetabolitesweremeasured
by LC/MS/MS using choline 1,1,2,2 d4 (d4 choline, Cambridge Isotope
Lab) as an internal standard. The chromatographic gradient employed
was as previously reported14 and speciﬁc parent to daughter transitions
in positive ion multiple reaction monitoring mode were 8566 for
d9 TMAO, 11369 for d9 choline, 12768 for d9 betaine, and
10860 for d4 choline. In additional studies, the role of gut ﬂora in
TMAO formation from dietary betaine was determined in C57BL/6J
mice by performance of oral (gavage) d9 betaine challenge. Mice were
housed in conventional cages in the absence or presence of a cocktail
of broad spectrum antibiotics added to the drinking water previously
shown to suppress gut ﬂora.14
Statistical analysis
Student’s t test or Wilcoxon rank sum test for continuous variables
and x2 test for categorical variables were used to examine the difference
between groups. Kaplan Meier analysis with Cox proportional hazards
regression was used for time to event analysis to determine hazard ratio
(HR) and 95% conﬁdence intervals (95% CI) for MACE. Stratiﬁcation
between median levels of choline, betaine, and TMAO levels was per
formed. Adjustments were made for individual traditional risk factors in
cluding age, sex, systolic blood pressure, low density lipoprotein
cholesterol, high density lipoprotein cholesterol, smoking, diabetes mel
litus, and hs C reactive protein to predict incident 3 yearMACE risks. All
analyses performed used R 2.8.0 (Vienna, Austria). P, 0.05 was
considered statistically signiﬁcant.
Results
Baseline characteristics and relation
of plasma choline and betaine levels
and cardiovascular risks
Table 1 shows the baseline characteristics of the study population.
The median (inter quartile ranges) for choline, betaine, and TMAO
plasma levels was 9.8 (7.9 12.2) mM, 41.1 (32.5 52.1) mM, and 3.7
(2.4 6.2) mM, respectively. Modest but statistically signiﬁcant corre
lations were noted between TMAO and choline (r ¼ 0.33, P,
0.001) and between TMAO and betaine (r ¼ 0.09, P, 0.001).
As illustrated in the Kaplan Meier analyses shown in Figures 1 and
2, a graded increase in risk for MACE was observed with increasing
plasma levels of either choline or betaine. Higher plasma choline or
betaine levels were each associated with increased risk for MACE
(1.9 fold and 1.4 fold, respectively; Quartile 4 vs. 1, P, 0.01, each;
Table 2). This is lower than the 2.5 fold increased risk for MACE
observed with increasing TMAO levels observed in the cohort
(Quartile 4 vs. 1, P, 0.01), similar to previous reports.17 Following
adjustments for traditional risk factors and hs C reactive protein,
elevated choline [hazard ratio, 1.34 (95% CI, 1.03 1.74, P, 0.05)],
and betaine levels [hazard ratio, 1.33 (95% CI: 1.03 1.73,
P, 0.05)] each predicted increased MACE risk (Table 2).
Interaction between choline, betaine, and
trimethylamine-N-oxide in predicting
future major adverse cardiac event risk
Choline, betaine, and TMAOwere previously shown to be metabo
lites of dietary PC and are each independently associated with the
prevalenceofCVD.14 In addition, dietary choline servesas a substrate
to ultimately produce TMAO.14 To directly test whether dietary
betaine can serve as a substrate for generation of TMAO similar to
choline,weperformedoral (gavage) challenges inmicewith synthetic
isotope labelled choline or betaine. First, C57BL/6J mice were fed
isotope labelled choline (d9 trimethyl choline) via gavage. After an
initial lag period, a rapid increase in plasma levels of the
d9 isotopologue of TMAOwas observed that peaks at4 h follow
ing ingestion, and then disappears rapidly within the subsequent 4 h
period. In comparison, plasma d9 choline levels peaked earlier
(within 1 h) following ingestion (Figure 3A and D). Although there
are reports that some bacterial species can cleave betaine to
produce TMA,22 to date, there have been no demonstrations that
TMAO can be produced from oral ingestion of betaine in animals.
We next examined whether oral betaine ingestion can produce
TMAO. C57BL/6J mice were similarly challenged with isotope
labelled betaine (d9 trimethyl betaine) via gavage, and plasma
levels of analytes monitored before vs. following ingestion. Similar
to the time course observedwith d9 choline ingestion, time depend
ent increases in the plasma levels of the anticipated d9 isotopologue
of TMAOwereobserved following oral ingestion of d9 betaine, with
peak level observed within 4 h. Further, following oral ingestion,
d9 betaine levels increased rapidly (peak level within 1 h), and then
disappeared gradually (Figure 3E). These results directly demonstrate
for the ﬁrst time that oral betaine can serve as a precursor for TMAO
formation. Of note, however, compared with comparable oral chal
lenge of d9 choline,14 betainewas a far poorer precursor for TMAO,
as it produced100 fold lessd9 TMAO(Figure3A andB). Toassess the
requirement of gut ﬂora in dietary betaine dependent formation of
TMAO, parallel studies were performed in mice following suppres
sion of gut ﬂora with an oral cocktail of poorly absorbed antibiotics
(3 weeks). Notably, no detectable d9 TMAO was observed in
plasma following oral d9 betaine challenge (Figure 3C), consistent
with gut ﬂora involvement in oral betaine metabolism into TMAO.
To further investigated the interaction between plasma levels of
either choline or betaine and TMAO vs. incident risk for MACE,
we constructed a model that included plasma levels of all three PC
Figure 1 Kaplan Meier estimates of freedom from major
adverse cardiac events (death, myocardial infarction, or stroke)
and plasma levels of choline. Data are shown for 3903 participants
in the clinical outcome study according to quartiles of plasma levels
of choline. The P value is for all comparisons.
Figure 2 Kaplan Meier estimates of freedom from major
adverse cardiac events (death, myocardial infarction, or stroke)
and plasma levels of betaine. Data are shown for 3903 participants
in the clinical outcome study according to quartiles of plasma levels
of betaine. The P value is for all comparisons.
Table 1 Baseline characteristics
Characteristic Value
Age (years) 63 + 11
Male sex (%) 64
History of cardiovascular disease (%) 65
History of coronary artery disease (%) 61
History of myocardial infarction (%) 41
Hypertension (%) 72
Diabetes mellitus (%) 31
Cigarette smoking (%) 65
LDL cholesterol (mg/dL) 96 (78 116)
HDL cholesterol (mg/dL) 34 (28 41)
Triglycerides (mg/dL) 118 (85 169)
High sensitivity C reactive protein (mg/L) 2.4 (1.1 5.9)
Betaine (mM) 9.8 (7.9 12.2)
Choline (mM) 41.1 (32.5 52.1)
TMAO (mM) 3.7 (2.4 6.2)
Values expressed in means+ standard deviation or median (inter-quartile range).



plasma levels of choline and betaine,which individually are associated
with poorer prognosis, only confer this added risk when associated
with concomitant TMAO elevation. In other words, subjects in
whom one observes the absence of high TMAO levels despite high
choline andbetaine levels (i.e. lowTMAOproducers) are signiﬁcantly
less likely to have an adverse cardiovascular event than thosewith in
testinal microbiota that readily produces TMA and TMAO (i.e. high
TMAO producers).
Conclusion
Elevatedplasma levels of choline andbetaine areeach associatedwith
poor prognosis even after adjusting for traditional cardiovascular risk
factors. However, high choline and betaine levels are associatedwith
higher risk of future MACE only with concomitant increased level of
TMAO.
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